[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective

被引:0
作者
Francesca Spada
Davide Campana
Giuseppe Lamberti
Riccardo Laudicella
Renato Dellamano
Luca Dellamano
Oscar Leeuwenkamp
Sergio Baldari
机构
[1] European Institute of Oncology (IEO),Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors
[2] IRCCS,Division of Medical Oncology
[3] IRCCS Azienda Ospedaliero-Universitaria di Bologna,Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and of Morpho
[4] University of Messina,Functional Imaging
[5] ValueVector,undefined
[6] Advanced Accelerator Applications/A Novartis Company,undefined
来源
European Journal of Nuclear Medicine and Molecular Imaging | 2022年 / 49卷
关键词
Cost-consequence analysis; Everolimus; Gastro-enteropancreatic neuroendocrine tumour; Healthcare costs; Italy; Lutetium; Peptide receptor radionuclide therapy; Progression-free survival; Somatostatin receptor agonists; Sunitinib;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2037 / 2048
页数:11
相关论文
共 155 条
[1]  
Dasari A(2017)Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States JAMA Oncol 3 1335-1342
[2]  
Shen C(2019)Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015 Br J Cancer 121 966-972
[3]  
Halperin D(2016)Italian cancer figures - report 2015. The burden of rare cancers in Italy Epidemiol Prev 40 1-120
[4]  
Zhao B(2005)Current status of gastrointestinal carcinoids Gastroenterology 128 1717-1751
[5]  
Zhou S(2016)ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site Neuroendocrinology 103 172-185
[6]  
Xu Y(2014)Lanreotide in metastatic enteropancreatic neuroendocrine tumors N Engl J Med 371 224-233
[7]  
Genus TSE(2009)Placebo-controlled, double-blind, prospective, randomised study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 4656-4663
[8]  
Bouvier C(2016)Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study Lancet 387 968-977
[9]  
Wong KF(2011)Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 514-523
[10]  
Srirajaskanthan R(2011)Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 501-513